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Chronic kidney disease (CKD) is an increasingly com-
mon public health concern with a global prevalence of 
~10%1. This disease now ranks as the 12th leading cause 
of death worldwide1. CKD results from a heterogeneous 
group of conditions that lead to a progressive and irre-
versible impairment in kidney function. It is defined as a 
reduction in estimated glomerular filtration rate (eGFR) 
to <60 ml/min/1.73 m2 and/or the presence of markers 
of kidney damage on at least two occasions at least 
3 months apart2.
CKD is independently associated with cardiovas-
cular disease3. As eGFR decreases, the risks of major 
cardiovascular events, cardiovascular mortality and 
all- cause mortality increase4. Importantly, patients with 
stage 1–3 CKD (eGFR >30 ml/min/1.73 m2) are more 
likely to die from cardiovascular disease than they are 
to reach kidney failure4,5 and around 50% of patients 
with kidney failure die from cardiovascular causes6. 
Not only are cardio vascular events more common in 
patients with CKD, but outcomes following such events 
are worse than in the general population7. Almost 8% of 
global cardiovascular deaths in 2017 were attributable 
to CKD1.
Hypertension is both a cause and a consequence of 
CKD. As kidney function declines, blood pressure rises, 
and more than 85% of patients with CKD are hyper-
tensive8. Thus, reducing blood pressure in CKD is a key 
therapeutic strategy that not only slows the progres-
sion to kidney failure but also reduces cardiovascular 
risk9. However, more than 30% of patients with CKD 
require four or more antihypertensive agents to achieve 
adequate blood pressure control and up to 50% never 
reach their target blood pressure8. Uncontrolled hyper-
tension promotes the development of left ventricular 
hypertrophy (LVH). The prevalence of LVH increases 
as kidney function declines and it is present in ~50% 
of patients with an eGFR of <25 ml/min/1.73 m2 (ref.10). 
Alongside hypertension and LVH, arterial stiffness, 
endothelial dysfunction and proteinuria are character-
istic features of CKD and important independent 
predictors of cardiovascular disease4,11–14.
Current evidence- based management of CKD is lim-
ited to blockers of the renin–angiotensin–aldosterone 
system (RAAS) that slow CKD progression4,8. Sodium–
glucose co- transporter 2 (SGLT2) inhibitors, which were 
originally developed for the treatment of type 2 diabetes 
mellitus (T2DM), have also now been shown to improve 
kidney and cardiovascular end points in patients with 
and without T2DM15,16. However, an urgent unmet need 
remains for novel treatments17. The ideal therapy would 
provide direct renoprotection and reduce proteinuria, 
while also offering broad cardiovascular protection. 
The apelin system has exciting therapeutic poten-
tial in this regard. In this Review, we focus on current 
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understanding of the apelin system, its cardiovascular 
and renal benefits, and the next steps required to explore 
its utility as a potential therapy for CKD.
Biology of the apelin system
The apelin system comprises the apelin receptor and 
its two endogenous ligands, apelin and elabela/toddler 
(ELA; also known as apelin receptor early endogenous 
ligand).
Apelin receptor
The APLNR gene (also known as APJ) was identified 
and cloned18 in 1993. This gene was found to encode 
the apelin receptor, a novel G protein- coupled recep-
tor (GPCR) that has ~50% homology with the type 1 
angiotensin II (AT1) receptor. The apelin receptor 
system opposes the actions of angiotensin II (Ang II) 
agonism at the AT1 receptor in vitro and in vivo19–27. In 
the cardiovascular system, apelin and AT1 receptors are 
co- expressed. The apelin receptor is highly conserved 
between species with ~90% sequence similarity between 
mouse, rat and human proteins28. Only one apelin recep-
tor has been identified in mammals, although two are 
expressed in fish and amphibians29–31.
Apelin receptor ligands
The two endogenous ligands of the apelin receptor are 
products of distinct genes, which is unusual for a pep-
tide–ligand GPCR. The first to be discovered, apelin 
(encoded by APLN), was identified in 1998 and the sec-
ond, ELA (encoded by APELA), was identified in 2013 
(refs32–35).
Apelin. Apelin peptides are produced by C- terminal 
cleavage of a 77- amino- acid precursor, pre- pro- 
apelin. Peptide fragments of varying lengths circulate 
in vivo; the major isoforms are apelin-36, apelin-17 
and apelin-13 (ref.28) (fig. 1a). The pyroglutamated 
form of apelin-13, [Pyr1]apelin-13, is structurally 
more resistant to metabolism by aminopeptidases than 
apelin-13 and is the most abundant apelin isoform in the 
cardiovascular system and human plasma36,37.
The mechanisms of apelin peptide metabolism are 
not yet fully defined. Experimental evidence suggests 
that furin (also known as PCSK3), plasma kallikrein and 
neprilysin cleave apelin peptides, but only neprilysin has 
been shown to completely inactivate these peptides27,38–41. 
This finding is of interest when considering the cardio-
protective effects of neprilysin inhibition in heart failure42. 
The mechanisms that underlie these effects remain 
undefined but prevention of the neprilysin-mediated 
degradation of apelin peptides could potentially 
contribute.
The carboxypeptidase angiotensin- converting 
enzyme 2 (ACE2) has been clearly demonstrated to 
cleave apelin isoforms both in vitro and in vivo, result-
ing in the removal of the common C- terminal pheny-
lalanine43–45. This enzyme is highly expressed on the 
surface of lung alveolar epithelial cells and entero-
cytes and is expressed at lower levels in most organs 
including kidney and heart and on arterial and venous 
endothelial cells45–47. ACE2 promotes vasodilatation by 
converting Ang II into angiotensin-1-7 (Ang(1-7))43. 
In addition, ACE2 acts as a functional cellular entry 
receptor for severe acute respiratory syndrome coronavi-
ruses, including SARS- CoV-2, which causes COVID-19 
(refs48–50). ACE2 was thought to inactivate [Pyr1]
apelin-13 (ref.44); however the [Pyr1]apelin-13 metab-
olite, [Pyr1]apelin-13(1–12), is detectable in human tis-
sues and retains biological activity in vitro and in vivo 
although it is less active than [Pyr1]apelin-13 (refs44,45). 
In healthy volunteers who received [Pyr1]apelin-13 
infusions, the major metabolite generated in the plasma 
was [Pyr1]apelin-13(1–12); [Pyr1]apelin-13(1–10) and [Pyr1]
apelin-13(1–6) were also identified51.
Elabela. ELA is a 54- amino- acid peptide that is pre-
dicted to be processed to form mature peptides includ-
ing ELA-32, ELA-21 and ELA-11 (fig. 1b). The discovery 
of ELA as the second endogenous ligand for the apelin 
receptor provided an explanation for the unexpected 
and marked discrepancy between the phenotypes of 
apelin receptor- knockout mice, which were not born in 
expected Mendelian ratios and had substantial cardio-
vascular developmental defects, and apelin- knockout 
mice, which developed normally52.
In zebrafish, most ELA mutants die early in devel-
opment as a result of cardiovascular abnormalities, 
including poorly developed or absent hearts. This phe-
notype could be rescued by injection of ELA, and the 
cardiovascular abnormalities could be recapitulated by 
knocking out the apelin receptor but not by knocking 
out apelin30,34,35,53.
Mice that lack ELA show low- penetrance embryonic 
lethality and cardiovascular abnormalities; however, 
their phenotype differs from that of apelin receptor 
knockouts54. Loss of ELA leads to yolk sac vascular 
remodelling defects with cardiac abnormalities and dis-
rupted fetal circulation, whereas mice with loss of the 
apelin receptor have a lower incidence of such defects 
and some embryos show abnormal tail bending. The 
abnormalities in coronary vascularization in ELA 
knockouts and apelin receptor knockouts may be over-
come by alternative progenitor cell pathways as develop-
ment progresses, perhaps explaining the low- penetrance 
lethality55. ELA is detectable in human plasma but its 
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Expression of the apelin system
Apelin and the apelin receptor are widely expressed 
within the central nervous system and peripheral 
organs. In rodents and humans, apelin receptor mRNA 
is detected in many tissues, particularly in brain, spinal 
cord, placenta, lung, heart, kidney, adipose tissue and 
skeletal muscle57–60. Apelin receptor protein has been 
identified in the brain, spinal cord, heart, kidney and 
lung of rats and humans59,61,62. In human heart, apelin 
receptor is expressed by cardiomyocytes, endothelial 
cells of the endocardium and intramyocardial blood 
vessel, endothelial cells and smooth muscle of conduit 
artery and vein59,61,62. Within the kidney, apelin receptor 
protein localizes to the cortex and vasculature61,62.
In humans and rats, mRNA encoding apelin is 
widely expressed throughout the brain, spinal cord, 
lung, kidney, heart and stomach with lower expression 
in other tissues33,58,59,63. In the periphery, apelin protein 
localizes predominantly to vascular endothelial cells, for 
example, in human heart, kidney and adrenal gland and 
to the endocardial endothelial cells that line the atria 
and ventricle64. Apelin is also an adipokine65 that local-
izes to adipose tissue and is produced by and secreted 
from human and rodent adipocytes60,66. However, apelin 
does not seem to be a major circulating hormone, and 
plasma concentrations are lower than tissue levels36,67. 
Given this finding and the similar locations of ape-
lin peptide and apelin receptor expression, it seems 
probable that the apelin system has a predominantly 
autocrine or paracrine mechanism of action. In con-
trast to apelin, ELA was initially reported to show 
kidney- specific expression in adult rat, largely confined 
to the renal tubules, but was subsequently identified in 
rodent heart68–70. To date, human studies have detected 
ELA expression only on the vascular endothelium and 
within the kidney56,71.
Apelin receptor binding and signalling
The endogenous apelin isoforms bind with nanomo-
lar affinity to their cognate receptor in cell expres-
sion systems and in rat and human cardiovascular 
tissues45,57,59,61,67,72,73. However, structure–activity studies 
suggest that the longer isoforms, such as apelin-36, and 
particularly apelin-17, have somewhat higher affin-
ity than the shorter isoforms such as [Pyr1]apelin-13 
(refs45,74,75). The N- terminal RPRL sequence of [Pyr1]
apelin-13, which is present in all longer apelin isoforms, 
is required for receptor binding with some contribution 
from other residues such as Pro12 (refs76–78) (fig. 1a). 
The smallest apelin fragment to retain biological acti-














































































MetCys LeuPro His Arg Val Pro Phe ProSer C
ArgLys Phe GlnArg Arg Arg Leu Ser His Lys Gly Pro Met Pro PhePro C
Apelin-13 Gln Arg Arg Leu Ser His Lys Gly Pro Met Pro PhePro C








Fig. 1 | The peptide sequences of apelin and elA isoforms. a | The amino acid sequences of apelin-36, apelin-17 , 
apelin-13 and [Pyr1]apelin-13 aligned by the C terminus, which is crucial for receptor binding and biological activity.  
The N- terminal Gln residue of apelin-13 undergoes translational modification to pyroglutamate, which increases resistance 
to metabolism by aminopeptidases. The resulting pyroglutamated form of apelin-13, [Pyr1]apelin-13, is the most abundant 
apelin isoform in humans34,35. b | The predicted amino acid sequences of ELA-32, ELA-21 and ELA-11 isoforms23,33. The  
N- terminal Gln of ELA-32 is predicted to undergo transformation to pyroglutamate. ELA-32 and ELA-21 form bridges 
between Cys residues. The occurrence and relative abundance of ELA isoforms have not yet been confirmed experimentally. 
Apelin and ELA isoforms have similar physicochemical properties, particularly within the C terminus.
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To date, only one crystal structure has been reported 
for the apelin receptor in complex with a 17-amino- 
acid non- endogenous apelin agonist80. Substantial 
mutation was required for successful crystallization of 
the receptor. However, using this structure in combina-
tion with molecular dynamic simulations and molecular 
modelling, the study demonstrated a two- site peptide–
ligand binding mode. This ‘message–address’ concept 
of peptide binding was also suggested by earlier studies, 
including one in which amino acids in the N- terminal 
tail and first extracellular loop were shown to be impor-
tant both for folding of the receptor protein and bind-
ing of apelin peptides81. In another structural study, the 
upper face of the apelin receptor binding site was visual-
ized using 3D homology models, and the interactions of 
basic residues in the N- terminal RPRL of [Pyr1]apelin-13 
with acidic residues in extracellular loops I and II as 
well as the interface between extracellular loop III and 
transmembrane VII were confirmed using site- directed 
mutagenesis82.
The ELA peptides show little sequence similarity to 
apelin although the predicted isoforms ELA-32, ELA-21 
and ELA-11 bind to the apelin receptor in human heart; 
ELA-32 bound with subnanomolar affinity, ELA-21 
with nanomolar affinity (comparable to that of [Pyr1]
apelin-13) and the shortest isoform, ELA-11, bound 
with affinity an order of magnitude lower than that of 
the other peptides56. An alanine scan and mutagene-
sis analysis suggested that apelin and ELA peptides 
engage with different residues in rat and human apelin 
receptors83.
The apelin receptor couples to pertussis toxin- 
sensitive inhibitory G proteins (Gαi/o) with subsequent 
activation of extracellular- regulated kinases (ERKs) and 
phosphoinositide 3- kinase (PI3K)–AKT (also known as 
protein kinase B (PKB)) signalling cascades57,84–87 (fig. 2). 
These cascades lead to a broad range of physiological 
effects that are dependent on the type of cell that is 
activated. All putative apelin and ELA isoforms elicit 
canonical Gi- mediated inhibition of adenylate cyclase, 
which results in inhibition of cAMP45,56,67,72,84. Similar to 
other GPCRs, the apelin receptor can engage with other 
heterotrimeric G proteins, particularly Gq, resulting in 
downstream stimulation of phospholipase C (PLC) and 
AMP- activated protein kinase (AMPK) pathways88,89.
Following activation, GPCRs can be uncoupled 
from their G proteins and internalized via recruitment 
of β- arrestins to the receptor. The extent and kinetics of 
apelin receptor- mediated internalization may be iso-
form specific, at least in vitro, with apelin-36 suggested 
to produce more prolonged internalization than [Pyr1]
apelin-13 (refs72,90–92). For successful translation of ape-
lin receptor agonists to the clinical setting, the finding 
that GPCR ligands may preferentially activate a subset 
of the signalling repertoire of a GPCR or indeed stim-
ulate some signalling pathways and inhibit others, so 
called ‘biased signalling’, is an important discovery93. 
Compared with [Pyr1]apelin-13, longer apelin ligand 
isoforms such as apelin-36, apelin-17, ELA-32 and 
ELA-21 have been shown to exhibit some bias towards 
β- arrestin recruitment45,56,73. The in vivo relevance of 
these observations to apelin receptor physiology or 
pathophysiology remains to be determined.
Ligand- independent signalling through the apelin 
receptor has also been reported19,94 and may be patho-
logically important. Phosphorylation of ERK1 and ERK2 
downstream of Ang II- mediated activation of AT1 recep-
tor was inhibited in cells that co- expressed the apelin 
receptor and this inhibition was abolished by apelin in 
a pertussis toxin- sensitive manner19. Subsequently, 
genetic loss of the apelin receptor was demonstrated to 
protect against cardiac hypertrophy and heart failure in a 
chronic pressure overload mouse model, whereas loss of 
apelin had no effect94. This discrepancy could potentially 
be explained by the later discovery of ELA. However, 
isolated cardiomyocytes from apelin receptor- knockout 
mice exhibited a reduced response to stretch, implying 
that the apelin receptor can act as a mechanosensor even 
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Fig. 2 | Apelin receptor activation leads to a broad range of physiological actions 
that are mediated by several signalling pathways. In vascular endothelial cells, 
binding of apelin or elabela/toddler (ELA) to the apelin receptor results in Gαi- mediated 
inhibition of cAMP production and activation of phosphoinositide 3- kinase (PI3K)–AKT 
signalling cascades, leading to vasodilatation. In cardiomyocytes, activation of the apelin 
receptor leads to a Gαq- mediated increase in cardiac contractility and cardiac output 
through activation of the phospholipase C (PLC)–protein kinase C (PKC) pathway with 
subsequent enhanced activity of the Na+/H+ exchanger (NHE) and increased intracellular 
pH. The increase in intracellular Na+ activates the Na+/Ca2+ exchanger (NCX), leading to  
a rise in intracellular calcium and increased myocardial contractility. Apelin-13 is thought 
to promote cardiomyocyte hypertrophy via PI3K–AKT–ERK1/ERK2–p70S6K and PI3K- 
induced autophagy (not shown). The metabolic effects of apelin receptor activation have 
been proposed to be mediated via Gαi and Gαq. Signalling via β- arrestin leads to apelin 
receptor desensitization and internalization. The internalized receptor is targeted for 
degradation or recycled to the cell surface. β- Arrestin- mediated signalling may also 
contribute to the actions of apelin. DAG, diacylglycerol; eNOS, endothelial nitric oxide 
synthase; ERK1, extracellular signal- regulated kinase 1; GRKβ: G protein coupled receptor 
kinase-β; IP3, inositol tris-phosphate; MEK1, mitogen- activated protein kinase 1;  
NO, nitric oxide; pAKT, phosphorylated AKT; PIP2, phosphatidylinositol 4,5- bisphosphate; 
p70S6K, p70 ribosomal S6 kinase.
‘Message–address’ concept 
of peptide binding
The concept that agonists 
contain two distinct parts: one 
determines receptor efficacy 
and activation (the ‘message’); 
the other influences receptor 
selectivity (the ‘address’).
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was abrogated by knockdown of β- arrestins and blunted 
by the addition of apelin94. The apelin receptor might 
therefore have pro- hypertrophic effects via β- arrestin 
signalling in the absence of ligand and anti- hypertrophic 
effects via β- arrestin- independent pathways when 
activated by apelin.
Clinical targeting of the apelin system
As apelin peptides have a half- life of only a few minutes 
in humans95–97, and rapid receptor desensitization via 
coupling to β- arrestins has been reported98, clinical 
studies of the apelin system are challenging. These issues 
have led to efforts to produce apelin receptor agonists 
and antagonists that may be used as pharmacological 
probes to explore the role of the system in health and 
disease. Clear understanding of the relevant signal-
ling pathways is essential to enable the development of 
appropriately targeted therapeutic agents.
Apelin analogues with enhanced biological activity 
compared with the endogenous peptides and resis-
tance to degradation have now been developed99,100. 
In a human forearm blood flow study, a cyclic apelin 
peptide mimetic, MM07, which has an extended half- 
life, showed biased agonism to beneficial G protein path-
ways and enhanced vasodilatation compared with [Pyr1]
apelin-13 (ref.97). Similarly, another apelin mimetic pep-
tide bound to anti- serum albumin domain antibodies to 
extend its half- life had in vivo potency, lowering blood 
pressure and increasing cardiac contractility, stroke 
volume, heart rate and cardiac output in rodents75.
From a clinical perspective, the ideal agent would 
likely be a small- molecule compound biased towards 
G protein signalling that does not effectively recruit 
β- arrestins and, therefore, limits receptor desensitization 
and subsequent downregulation with continued clinical 
use97,101. One such small molecule, CMF-019, has been 
developed. This molecule exhibits high affinity for the 
apelin receptor and has in vivo functional activity with 
a bias towards G protein signalling101. However, its use 
as an oral agent may be limited by its poor solubility.
Two small- molecule agonists of the apelin recep-
tor, AMG-986 and AMG-8123, with extended plasma 
half- lives (>2–4 h in rats and dogs) have also been devel-
oped. These molecules have a high affinity for the apelin 
receptor and were shown to be functional in vivo and in 
animal models of heart failure102. Other small- molecule 
apelin agonists are also in development28.
Although several compounds have been suggested to 
act as apelin antagonists, contradictory studies suggest 
that some also have agonist activity. The field would ben-
efit from the identification of well- characterized antag-
onists. If successful, the development of apelin agonists 
and antagonists could lead to a new era of research and 
therapeutics based on the apelin system28.
Apelin in cardiovascular physiology
The apelin system is a broad regulator of physiology 
(fig. 3). In the cardiovascular system, apelin has roles 
in control of vascular tone, blood pressure, inotropy, 
angiogenesis and haemostasis.
Vascular function and blood pressure
Apelin has well- described effects on the vasculature. 
Preclinical studies established that in healthy vessels, 
apelin acts on the endothelium to promote vasodilata-
tion through an increase in nitric oxide (NO)21,103 (fig. 2). 
By contrast, in endothelium- denuded vessels, apelin 
acts directly on vascular smooth muscle cells to pro-
mote vasoconstriction36,45. Various animal models have 
demonstrated that multiple apelin peptides lead to a 
rapid, transient and dose- dependent reduction in blood 
pressure, with variable effects on heart rate33,45,72,104,105. 
The blood pressure- lowering action of apelin in vivo is 
also NO dependent21,105.
In humans, infusions of [Pyr1]apelin-13, [Pyr1]
apelin-13(1–12) and apelin-36 led to reproducible, dose- 
dependent and NO- dependent arteriolar vasodila-
tation in the forearm45,95,97. In keeping with in vitro data 
that show slower dissociation of apelin-36 than [Pyr1]
apelin-13 from the apelin receptor, this peptide has a 
more prolonged action in humans57,95. Systemic studies 
in healthy volunteers demonstrated that apelin reduces 
blood pressure; [Pyr1]apelin-13 led to a 5–10% fall 
in blood pressure, reduced peripheral vascular resis-
tance and caused a small increase in heart rate that was 
most likely compensatory96. The effects of apelin on 
venous tone are less consistent. One study found that 
[Pyr1]apelin-13 reversed noradrenaline- induced pre- 
constriction of dorsal hand veins, whereas another 
showed no effect95,97. However, this discrepancy may be 
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Fig. 3 | physiological actions of the apelin system in different organs and tissues. 
Activation of the apelin receptor results in a broad range of physiological effects in  
central and peripheral tissues. Within the vasculature, the apelin system promotes vaso-
dilatation, subsequent lowering of blood pressure and angiogenesis and might also have 
antithrombotic effects. Apelin is a potent inotrope that increases myocardial Ca2+ sensi-
tivity and reduces cardiac preload and afterload. It also increases the conduction velocity 
within cardiomyocytes, has anti- arrhythmic effects and reduces myocardial hypertrophy 
and fibrosis. In the kidney, activation of the apelin system increases renal blood flow and 
diuresis and reduces inflammation and fibrosis. The apelin system also has a central role 
in the regulation of fluid homeostasis: apelin inhibits hypothalamic vasopressin release 
and reduces water intake. Finally, the apelin system has a range of metabolic effects.  
It promotes brown adipogenesis and mitochondrial biogenesis in white adipose tissue, 
increases muscle glucose uptake and utilization and increases insulin sensitivity.
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ELA also promotes vasodilatation, although its 
mechanism of action may differ from that of apelin. In 
preclinical studies, ELA relaxed pre- constricted mouse 
aortic rings in a dose- dependent manner and induced 
carotid artery vasodilatation in the rat70,71. In vivo data 
confirm that systemic infusions of both ELA and a bio-
active analogue, ELA(19–32), reduce blood pressure in 
rodents56,99. In contrast to apelin, ELA- induced vasodila-
tation is NO independent and only partly dependent on 
the endothelium71. The effects of ELA have not yet been 
investigated in humans.
Inotropy and conduction
Apelin acts via several signalling pathways and is the most 
potent endogenous inotrope discovered to date36,88,106,107 
(fig. 2). Mice with knockout of apelin develop a progres-
sive reduction in cardiac contractility that can be restored 
by apelin infusion108. Apelin administration accentuated 
sarcomere shortening in healthy rat cardiomyocytes and 
resulted in a dose- dependent increase in contractility in 
isolated perfused rat hearts88,106,109. Consistent with this 
finding, chronic [Pyr1]apelin-13 infusion increased 
cardiac output in vivo in mice110.
A number of apelin peptides have been shown 
to promote inotropy with subnanomolar potency 
in human paced atrial strips36,45. In a clinical study in 
healthy volunteers, intracoronary boluses of apelin-36 
and systemic infusions of [Pyr1]apelin-13 and 
apelin-36 increased cardiac output36,45,96. This effect 
was maintained in the setting of renin–angiotensin 
system (RAS) activation owing to either salt depletion or 
Ang II co- infusion24.
Clear evidence exists of antagonism between the 
apelin system and the RAAS. In addition to impaired 
contractility, apelin- deficient mice have reduced ACE2 
expression, and inhibition of AT1 receptors or infusion 
of Ang(1-7) rescued cardiac function and restored ACE2 
expression in these mice111. In addition, Ang II- induced 
cardiac dysfunction is enhanced by apelin deficiency112. 
Many inotropic agents result in LVH and subsequently 
increased mortality; however, apelin does not cause cel-
lular hypertrophy in animal studies110. This difference 
is likely a consequence of the systemic haemodynamic 
effects of apelin, which are in contrast to the effects 
of other inotropic agents and increase its appeal as a 
therapeutic agent.
ELA is also a positive inotrope in preclinical models. 
In isolated adult rat hearts, ELA-32 increased cardiac 
contractility70. This was replicated in a second study 
that also showed ELA(19–32) to be inotropic99. Further 
in vivo studies confirmed that in rats, ELA-32 increases 
cardiac contractility, ejection fraction and cardiac 
output56.
The apelin system has also been shown to influence 
cardiac conduction. Preclinical studies demonstrate that 
apelin increases conduction velocity within cardiomy-
ocytes and influences the cardiac action potential109,113. 
For example, apelin shortens the action potential in 
atrial myocytes via effects on multiple ion currents113.
Angiogenesis
Apelin is necessary for normal vascular development 
during embryogenesis114,115. Embryos with knockout of 
apelin initially show reduced- calibre blood vessels115. 
Other factors seem to be able to ‘rescue’ these vessels 
later in development, although these remain undefined. 
However, studies of ocular blood vessel formation 
show that apelin- knockout mice have impaired retinal 
vascularization and reduced responsiveness to pro- 
angiogenic factors such as vascular endothelial growth 
factor (VEGF) and fibroblast growth factor 2 (ref.116). 
Preclinical studies confirm that ELA also promotes 
angiogenesis by acting on the apelin receptor55,71.
Apelin expression is induced by hypoxia both in vitro 
and in vivo, and hypoxia- inducible factor 1α (HIF1α) 
promotes apelin gene transcription114,117,118. Interestingly, 
hypoxia- stimulated endothelial cell proliferation is pre-
vented by inhibition of the apelin pathway, suggesting 
that the apelin system contributes to physiological and 
pathophysiological regulation of blood vessel growth117.
In addition to its physiological role in vascular 
development, apelin might have a pathological role in 
promoting angiogenesis in various cancers (Box 1).
Haemostasis
Both apelin and the apelin receptor are expressed on 
human platelets. Apelin-13 inhibits platelet aggre-
gation induced by low (but not high) concentrations of 
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thrombin or collagen in vitro but does not seem to influ-
ence platelet activation by other stimuli such as throm-
boxane A2 or ADP119. The effects of apelin on platelets 
are mediated through inhibition of calcium mobiliza-
tion as well as the generation of NO119, which promotes 
platelet production of cGMP. The NO–cGMP pathway 
has a biphasic effect with low concentrations activating 
platelets and high concentrations being inhibitory120. 
Thrombin increases cGMP levels within platelets, pro-
moting their activation. The addition of apelin further 
increases cGMP levels, leading to inhibition of platelet 
activity119.
Animal data confirm the antithrombotic effect of 
apelin in vivo. Apelin- deficient mice are pro- thrombotic, 
with reduced tail bleeding time, enhanced plate-
let aggregation and faster thrombotic occlusion of 
venules compared with wild- type controls. Infusion 
of apelin-13 prolongs bleeding time in both wild- type 
and apelin- deficient mice119. Whether apelin also has an 
antithrombotic effect in humans has not yet been inves-
tigated. Current antiplatelet therapies focus on inhibition 
of cyclooxygenase 1 (using aspirin) or antagonism of the 
ADP P2Y12 receptor (using clopidogrel, prasugrel or 
ticagrelor). Thrombotic events can still occur in patients 
who are receiving antithrombotic combination thera-
pies, and an agent that provides broader cardiovascular 
protection while reducing the risk of thrombo- occlusive 
events would be very desirable.
Apelin in cardiovascular disease
The apelin system is dysregulated in cardiovascular dis-
ease, and beneficial effects of its activation have been 
shown in disease models. The apelin receptor is therefore 
an appealing target for pharmacological intervention.
Vascular actions of apelin in disease
CKD is characterized by medial vascular calcification 
and the development of arterial stiffness. This change 
in vascular structure alongside endothelial injury leads 
to endothelial dysfunction. Importantly, preclinical and 
clinical studies show that the vasodilatory effect of apelin 
persists even in states of endothelial dysfunction, and 
this effect seems to be independent of NO36,103. In this 
setting, apelin might act via a prostanoid- dependent 
mechanism. However, the available data are incon-
clusive, perhaps owing to the use of different cycloox-
ygenase inhibitors and their differential effects on 
downstream signalling36,103.
In clinical studies, patients with heart failure and 
healthy volunteers had equivalent dose- dependent 
vasodilatation of forearm vessels in response to [Pyr1]
apelin-13 (ref.96). In a mouse model of immune- mediated 
vascular injury after heart transplantation, apelin pro-
moted vascular repair and endothelial cell differentia-
tion and reduced immune cell adhesion121. This finding 
could have exciting therapeutic potential for similar 
immune- mediated vascular injury following kidney 
transplantation.
The vascular endothelium is an important regulator 
of coagulation. Endothelial release of tissue plasmino-
gen activator promotes fibrinolysis, and its activity is 
regulated by plasminogen activator inhibitor 1 (PAI1). 
In states of endothelial dysfunction, fibrinolysis may 
be impaired. A reciprocal relationship exists between 
expression of the apelin system, the AT1 receptor and 
PAI1 in patients with atrial fibrillation and thrombosis122. 
In left atrial appendages from these patients, expression 
of apelin and the apelin receptor was reduced and expres-
sion of AT1 receptors and PAI1 was increased compared 
with those from patients with sinus rhythm or with atrial 
fibrillation without thrombosis. In healthy mice, 3 weeks 
of treatment with Ang II promotes PAI1 gene expression, 
whereas similar exposure to apelin downregulates PAI1 
gene expression in preclinical models23. This finding 
may provide an additional mechanism by which apelin 
regulates haemostasis.
Atherosclerosis
The apolipoprotein E (Apoe)- knockout mouse is a 
widely used model of atherosclerosis. Mice that are 
deficient in both ApoE and apelin develop more athero-
matous lesions than Apoe- knockout mice, which in 
turn develop more atheromatous lesions than Apoe 
and apelin receptor- double- knockout mice123,124. The 
reasons for these contrasting data are unclear but it is 
noteworthy that mice that lack the apelin receptor show 
increased prenatal death, and those that do survive have 
cardiovascular malformations that likely contribute to 
accelerated atherosclerosis. The apelin receptor might 
have ligand- independent effects on the development 
of atherosclerosis, but such effects have not been noted 
in studies using apelin receptor- knockout mice. In the 
Apoe- knockout mouse, treatment with apelin alone 
had no effect on the development of atheromatous 
lesions123. However, administration of Ang II resulted 
in an increase in atherosclerotic lesions that was abro-
gated by coadministration of apelin, providing further 
evidence of functional interaction of the RAS and the 
apelin system in vivo123.
Heart failure
The available data suggest that the apelin system is 
upregulated early in heart failure and downregulated 
as the disease progresses125. Plasma apelin concentra-
tions show a similar pattern22,125–128. Evidence exists 
of functional crosstalk between the apelin system and 
the RAS in heart failure. In animal models, Ang II 
infusion results in downregulation of cardiac apelin 
mRNA and this effect can be inhibited by an angio-
tensin receptor blocker (ARB). Similarly, in animals 
with heart failure, downregulation of the apelin sys-
tem can be restored by an ARB22,129. Administration of 
l- NG- monomethylarginine (l- NAME), an inhibitor of 
NO synthesis, abrogated the beneficial effects of an ARB 
(olmesartan) on cardiac function and the apelin system 
in a heart failure model129. These findings together with 
the inotropic effect of apelin have led to sustained enthu-
siasm regarding the potential therapeutic role of apelin 
in heart failure.
Preclinical studies have demonstrated that apelin 
has inotropic effects in models of heart failure109,130. 
Moreover, systemic infusion of [Pyr1]apelin-13 resulted 
in a modest fall in blood pressure and systemic vas-
cular resistance and a ~10% increase in cardiac index 
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in patients with stable New York Heart Association 
Class II–IV heart failure symptoms and a left ventricular 
ejection fraction of <40% (or shortening fraction <20%) 
who were receiving optimized treatment96. Further 
studies found this improvement in cardiac output to be 
sustained during prolonged apelin infusion (6 h), with 
an associated increase in ejection fraction of ~10%24. 
At present, the utility of apelin in heart failure is limited 
by the lack of long- acting preparations.
Myocardial infarction
Studies in several preclinical models have demonstrated 
that apelin protects against ischaemic myocardial injury. 
Apelin- knockout mice show enhanced susceptibility 
to injury, with larger infarct size, increased ventri-
cular dilatation and increased mortality compared 
with wild- type controls100. Administration of apelin or 
an apelin analogue had protective effects in models of 
myocardial infarction, including improved functional 
recovery and a reduction in infarct size. These effects 
were most likely due to promotion of NO production 
and angiogenesis100,131.
Following any ischaemic injury, angiogenesis is 
stimulated to promote oxygen delivery to tissues. In a 
mouse model of myocardial infarction, overexpression 
of HIF1α reduced infarct size and the development of 
heart failure132. Apelin signalling is critically important 
in angiogenesis, APLN may be upregulated by HIF1α, 
and apelin- deficient animals have impaired angiogenic 
responses to ischaemia–reperfusion injury (IRI)100,118. 
Currently, following myocardial infarction, patients 
are treated with RAS blockers to reduce the detrimen-
tal effects of Ang II. Importantly, a preclinical study 
showed that combination treatment with apelin and the 
ARB losartan reduced infarct size by ~50%, compared 
with a ~30% reduction when either treatment was used 
individually133. This finding holds promise for future 
clinical studies in this area.
Arrhythmias
Clinical studies have shown that plasma apelin levels are 
reduced in patients with supraventricular tachycardias, 
including atrial fibrillation134,135. Moreover, apelin levels 
predict the recurrence of atrial arrhythmias136. Patients 
with atrial fibrillation have reduced atrial apelin levels, 
and apelin administration completely prevented the 
induction of atrial arrhythmias in mice with increased 
susceptibility owing to chronic intense exercise137. Atrial 
fibrillation is associated with a high risk of ischaemic 
stroke and is common in patients with CKD. The prev-
alence of atrial fibrillation increases as kidney function 
declines, reaching ~20% in patients not requiring kidney 
replacement therapy138,139. Decisions on anticoagulation 
in this patient group are complex as bleeding risk also 
increases as kidney function declines140. If targeting of 
the apelin system is able to protect against arrhythmia, 
this strategy could be particularly advantageous for 
patients with CKD.
Apelin in kidney physiology
Although widely expressed in human kidney, studies of 
the role of apelin in human kidney physiology are lack-
ing. Animal studies suggest that apelin has direct actions 
on the kidney that contribute to the regulation of renal 
haemodynamics and fluid homeostasis.
Glomerular haemodynamics
Glomerular blood flow is under the tight control of the 
RAS, which regulates both glomerular perfusion and 
GFR, and crosstalk exists between the RAS and the apelin 
system (fig. 4a). By increasing intracellular calcium levels, 
Ang II vasoconstricts both the afferent and efferent arte-
rioles, with a preferential effect on the efferent arteriole. 
In rats, apelin reverses Ang II- induced vasoconstriction 
of the afferent and efferent glomerular arterioles and 
causes a rapid fall in intracellular calcium levels. This 
vasodilatory action of apelin is dependent on an intact 
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Fig. 4 | The actions of apelin in the nephron. a | Apelin acts at the afferent and efferent arterioles to promote 
vasodilatation via production of nitric oxide (NO), opposing the action of angiotensin II (Ang II). b | Increased vasodilatation 
at the efferent arteriole directly increases blood flow through the vasa recta, leading to increased medullary blood flow 
and promoting diuresis. c | The action of apelin counteracts vasopressin signalling in the kidney tubules. In the principal 
cells of the collecting duct, apelin prevents vasopressin- induced translocation of aquaporin 2 (AQP2) channels to the 
apical membrane and therefore prevents water reabsorption. AT1 receptor, type 1 angiotensin II receptor; AVP, arginine 
vasopressin; Gi, inhibitory G protein α-subunit; Gs, stimulatory G protein α-subunit; V2R, vasopressin v2 receptor.
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endothelium and NO production141. As the vasa recta 
are supplied by the efferent arteriole, apelin- induced 
vasodilatation might promote diuresis through an 
increase in renal medullary blood flow (fig. 4b).
Tubular function
Apelin contributes to fluid homeostasis by opposing 
the actions of vasopressin, with crosstalk between the 
systems. Apelin, the apelin receptor and vasopressin 
co- localize within the magnocellular neurons of the 
supraoptic and paraventricular nuclei of the hypothal-
amus, and clear reciprocal regulation of the peptides 
exists142–144. Clinical studies in healthy volunteers support 
these findings, with changes in plasma osmolality accom-
panied by parallel reciprocal changes in vasopressin 
and apelin levels145.
Both central and peripheral injections of apelin pep-
tides and ELA promote diuresis in animals68,141,143,144,146. In 
addition, apelin acts directly on the renal tubule to pro-
mote a dose- dependent aquaresis without affecting renal 
sodium or potassium handling141,146. In vitro and in vivo 
studies suggest that this aquaresis is due to inhibition 
of aquaporin 2 channel insertion into the apical plasma 
membrane of the collecting duct146,147 (fig. 4c). Within the 
rodent kidney, ELA is more abundantly expressed than 
apelin and predominates in the medullary collecting 
ducts69. The specific mechanism of ELA- induced diure-
sis has not yet been defined. However, given that expres-
sion of ELA is restricted to the vascular endothelium and 
kidney in adults, a direct renal action would be expected.
Apelin in kidney disease
Several in vitro and in vivo studies have investigated the 
effects of the apelin system in kidney pathology. Apelin 
is protective in a broad range of diseases owing to its 
anti- inflammatory and anti- fibrotic effects and might 
also have important roles in certain kidney diseases.
Acute kidney injury
Acute kidney injury (AKI) affects 8–17% of hospitalized 
patients and >50% of those who are admitted to inten-
sive care148,149. Moreover, AKI is strongly associated with 
adverse outcomes including the development of CKD, 
kidney failure and death, although the mechanisms are 
poorly defined150. Studies in models of AKI suggest early 
upregulation of the apelin system that is followed by 
downregulation as injury progresses151,152. This dynamic 
change is similar to that seen in heart failure.
Both in vitro and in vivo data support a direct pro-
tective effect of apelin treatment in kidney IRI, which is 
a widely used model of AKI151,153. Following IRI in rats, 
twice- daily administration of apelin-13 for 3 days pro-
tected against tubular injury, the hallmark of AKI, and also 
limited functional kidney impairment151. Apelin-13 
also influenced injury- induced alterations in gene tran-
scription both in vitro and in vivo, preventing down-
regulation of apelin mRNA and upregulation of HIF1α 
and transforming growth factor β (TGFβ), which are 
important mediators of progressive injury. Upregulation 
of inflammatory markers such as intracellular adhesion 
molecule 1 and monocyte chemokine protein 1 was also 
reduced, as was apoptosis151. Importantly, apelin was 
protective when administered before IRI153, suggest-
ing potential clinical applications in settings where AKI 
might be anticipated, including kidney transplantation or 
cardiothoracic surgery. Renoprotective effects of apelin 
have also been reported in other models of AKI, such as 
cyclosporin A- induced tubular injury, suggesting that ape-
lin might protect against various renal insults, including 
drug- induced injury154.
ELA also protects against kidney IRI. Treatment 
with either ELA-32 or ELA-11 inhibited IRI- induced 
inflammation, apoptosis and fibrosis and preserved 
kidney function in a mouse model of unilateral ure-
teric obstruction155. Like apelin, specific ELA fragments 
have different signalling effects, with the shorter frag-
ment, ELA-11, being more protective than ELA-32 both 
in vitro and in vivo. The mechanism of action is not 
clear, as doses of peptide that conferred protection did 
not induce a change in intracellular cAMP, which would 
be expected with apelin receptor activation155. Apelin-13 
and ELA therefore seem to have different mechanisms 
of action and a synergistic effect has been suggested, 
with combination treatment offering greater protection 
against in vitro cell death155. Whether this finding could 
translate to synergy in humans and greater protection 
against AKI is unclear, but should be explored in clinical 
studies.
Diabetic kidney disease
Diabetic kidney disease (DKD) is the most common 
cause of kidney failure worldwide156. Hyperglycaemia 
alters glomerular haemodynamics, leading to glomeru-
lar hypertrophy, damage to the filtration barrier and the 
development of albuminuria. Preclinical studies suggest 
that expression of the apelin system is altered in DKD. 
Cultured mouse podocytes have been shown to down-
regulate APLNR mRNA157 but upregulate apelin receptor 
expression158 in response to a high- glucose environment. 
Ang II administration further increased APLNR mRNA 
downregulation in these cells157. Some studies in animal 
models of T1DM and T2DM have shown reduced kid-
ney expression of the apelin receptor and pre- pro- apelin, 
whereas others have shown the opposite157,159,160.
Definition of the role of the apelin system in DKD 
is limited by a lack of clinical studies and conflicting 
animal data161. In cultured mouse podocytes, apelin-13 
had anti- apoptotic effects157. In the Akita mouse model 
of T1DM, apelin-13 preserved glomerular architecture, 
reduced proteinuria and inhibited renal inflammation162. 
The researchers found that this protection was due, in 
part, to an inhibitory effect of apelin on diabetes- induced 
histone hyperacetylation. Similar protection was obser-
ved in Ove26 mice with T1DM in which apelin-13 was 
found to have antioxidant effects and prevent the loss of 
megalin expression in the proximal tubule, resulting in 
maintenance of albumin resorption159.
Conversely, in the KK- Ay mouse model of T2DM, 
apelin contributed to disease progression, worsening 
of albuminuria and creatinine clearance via detrimen-
tal effects on renal blood flow, podocyte apoptosis and 
autophagy158,160,163,164. In this model, F13A conferred pro-
tection, which was purported to reflect antagonism of 
the apelin receptor. However, whether this compound 
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is a true antagonist is unclear. Overall, the available pre-
clinical data suggest that apelin is protective in DKD. 
However, systemic application of apelin in patients with 
diabetes could potentially be limited by adverse effects 
such as the promotion of diabetic retinopathy (Box 2).
Disorders of fluid homeostasis
The relationship between the apelin system and vas-
opressin is disrupted in disorders of fluid homeosta-
sis. Syndrome of inappropriate antidiuretic hormone 
(SIADH) results in water retention due to vasopressin 
excess. Plasma copeptin is a reliable marker of vasopres-
sin secretion and the apelin to copeptin ratio indicates 
relative activation of these systems. Patients with SIADH 
have substantially elevated plasma vasopressin levels 
and modest increases in plasma apelin. The apelin to 
copeptin ratio is lower than anticipated in ~90% of these 
patients165.
Disruption of apelin–vasopressin balance is also seen 
in patients with polyuria and polydipsia syndromes. 
Parallel decreases in plasma apelin and copeptin levels 
occur in primary polydipsia and cranial diabetes insip-
idus, whereas parallel increases in these levels occur in 
nephrogenic diabetes insipidus, resulting in alterations 
in the apelin to copeptin ratio166. Alterations in circulat-
ing apelin are suggested to be adaptations to restore the 
balance of diuresis and antidiuresis; however, they seem 
to be unable to fully compensate. Kidney function may 
be impaired in disorders of fluid homeostasis as a direct 
consequence of the cause of the disorder (such as lithium 
toxicity or nephrogenic diabetes insipidus) or as a conse-
quence of hypovolaemia. The impact of reduced kidney 
function on circulating apelin levels is currently unclear.
Polycystic kidney disease
Autosomal dominant polycystic kidney disease 
(ADPKD) is the most common human monogenic dis-
ease. Vasopressin has an important role in the patho-
genesis of ADPKD, and vasopressin antagonists are 
the first licensed treatment for this disease. Patients 
with ADPKD have higher plasma copeptin and lower 
plasma apelin concentrations than healthy individuals167. 
Moreover, in ADPKD, plasma apelin concentration falls 
as kidney function declines and correlates negatively 
with TGFβ1, which is a marker of kidney fibrosis167,168. 
Although noteworthy, this finding does not enable 
conclusions to be drawn more broadly regarding ape-
lin levels in CKD given the close relationship between 
apelin and vasopressin. Little is known about the renal 
expression of the apelin system in ADPKD. However, the 
inhibitory effect of apelin on aquaporin 2 channel inser-
tion in the collecting duct146,147 suggests that treatment 
with apelin might be a potential alternative approach to 
use of the vasopressin 2 receptor antagonist tolvaptan. 
An aquaretic with direct anti- fibrotic effects on the kid-
ney and beneficial cardiovascular effects would be a very 
attractive treatment option for this at- risk patient group.
Kidney fibrosis
The development of glomerulosclerosis and interstitial 
fibrosis is the final common end point of many CKDs. 
In the early stages of kidney injury, upregulation of 
inflammatory and pro- fibrotic mediators occurs. Left 
unchecked, these mediators promote progressive fibro-
sis and a reduction in GFR. The RAS promotes kid-
ney fibrosis through the action of Ang II on the AT1 
receptor, and blockade of the system is beneficial in 
CKD169–171.
In vitro studies demonstrate that expression of the 
intrarenal RAS is regulated by the apelin system. For 
example, in collecting duct- derived M1 cells, ELA-32 
reduced expression of the (pro)renin receptor, prorenin 
and renin172. In mice, knockout of the (pro)renin receptor 
led to increased levels of apelin and ELA mRNA172. The 
impact of (pro)renin receptor knockout on the apelin 
receptor was dependent on the location of the knock-
out: nephron- specific knockout resulted in reduced 
medullary apelin receptor mRNA and protein, whereas 
collecting duct- specific knockout had no effect. Animal 
models confirm reciprocal regulation of the RAS and 
apelin systems. For example, in Dahl salt- sensitive 
rats, ELA-32 infusion prevented high- salt diet- induced 
upregulation of renin, AT1 receptor and AT2 receptor 
mRNA172.
Apelin has anti- fibrotic effects173, and ELA overex-
pression or ELA-32 peptide administration reduced 
renal fibrosis and inflammation in salt- sensitive 
rats172,174. In the unilateral ureteric obstruction model 
of kidney fibrosis, the apelin system is upregulated 
in the obstructed kidney with evidence of activation 
of the AKT–endothelial nitric oxide synthase (eNOS) 
pathway, which is stimulated by apelin175. In this model, 
losar tan, which blocks AT1 receptors, reduced kidney 
fibrosis and promoted activation of the AKT–eNOS 
path ways and expression of apelin mRNA. Intriguingly, 
inhibition of the apelin system using either an ape-
lin receptor antagonist or l- NAME abrogated the 
anti- fibrotic effect of losartan. Administration of 
l- NAME together with losartan increased fibrosis 
compared with controls175. In addition, the AT1 recep-
tor blocker, telmisartan, restored apelin receptor and 
pre- pro- apelin mRNA expression in a mouse model 























R e v i e w s
0123456789();: 
of T2DM157. These observations suggest that the 
anti- fibrotic effects of ARBs are partly mediated through 
crosstalk with the apelin system, probably through NO 
generation. It would be of great interest to investigate 
whether combined treatment with an ARB and apelin 
can act synergistically in the kidney, as has been seen 
in in a model of myocardial IRI133. If translated to clin-
ical studies, such synergistic benefits would represent a 
remarkable therapeutic advance for patients with CKD.
Conclusions
CKD is a global health problem and new treatments that 
delay progression to kidney failure are urgently needed. 
Targeting the apelin system is a promising strategy 
given its beneficial renal and cardiovascular effects. In 
addition, apelin positively affects lipid metabolism and 
improves glycaemic control by enhancing insulin sen-
sitivity and promoting glucose utilization176,177. These 
protective effects on metabolic health are particu-
larly attractive for patients with DKD. However, many 
unanswered questions remain. At present, no clinical 
studies exist of the effects of apelin on renal physiol-
ogy in either health or disease. In addition, the blood 
pressure- lowering and inotropic effects of apelin have 
been robustly demonstrated in healthy individuals and 
in patients with heart failure, but whether apelin has 
similar effects in patients with CKD who commonly 
have multiple comorbidities is unclear. Studies are now 
underway to answer these questions178. Moreover, cur-
rent therapeutic use of apelin in CKD would require 
systemic administration. The endogenous apelin system 
appears to have tissue- specific expression with parac-
rine or autocrine signalling. Systemic application might 
have undesirable off- target effects, such as promotion of 
pathological angiogenesis, which is an important con-
sideration for patients with multimorbidity. Overall, the 
apelin system clearly warrants further investigation and 
has exciting potential as a therapeutic target that could 
offer multi- system protection to improve outcomes for 
patients with kidney disease.
Published online xx xx xxxx
1. Bikbov, B. et al. Global, regional, and national burden 
of chronic kidney disease, 1990–2017: a systematic 
analysis for the Global Burden of Disease Study 2017. 
Lancet 395, 709–733 (2020).
2. Stevens, P. E. & Levin, A. Evaluation and management 
of chronic kidney disease: synopsis of the kidney 
disease: improving global outcomes 2012 clinical 
practice guideline. Ann. Intern. Med. 158, 825–830 
(2013).
3. Webster, A. C., Nagler, E. V., Morton, R. L. &  
Masson, P. Chronic kidney disease. Lancet 389, 
1238–1252 (2017).
4. Gansevoort, R. T. et al. Chronic kidney disease and 
cardiovascular risk: epidemiology, mechanisms,  
and prevention. Lancet 382, 339–352 (2013).
5. Keith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B. 
& Smith, D. H. Longitudinal follow- up and outcomes 
among a population with chronic kidney disease in a 
large managed care organisation. Arch. Intern. Med. 
164, 659–663 (2004).
6. Schiffrin, E. L., Lipman, M. L. & Mann, J. F. Chronic 
kidney disease: effects on the cardiovascular system. 
Circulation 116, 85–97 (2007).
7. Anavekar, N. S. et al. Relation between renal 
dysfunction and cardiovascular outcomes after 
myocardial infarction. N. Engl. J. Med. 351,  
1285–1295 (2004).
8. Muntner, P. et al. Hypertension awareness, treatment, 
and control in adults with CKD: results from the 
Chronic Renal Insufficiency Cohort (CRIC) study.  
Am. J. Kidney Dis. 55, 441–451 (2010).
9. Cheung, A. K. et al. Effects of intensive BP control in 
CKD. J. Am. Soc. Nephrol. 28, 2812–2823 (2017).
10. Levin, A., Singer, J., Thompson, C. R., Ross, H. & 
Lewis, M. Prevalent left ventricular hypertrophy in the 
predialysis population: identifying opportunities for 
intervention. Am. J. Kidney Dis. 27, 347–354 (1996).
11. Townsend, R. R. et al. Aortic PWV in chronic kidney 
disease: a CRIC ancillary study. Am. J. Hypertens. 23, 
282–289 (2010).
12. Kim, E. D. et al. Associations between kidney disease 
measures and regional pulse wave velocity in a large 
community- based cohort: the Atherosclerosis Risk  
in Communities (ARIC) study. Am. J. Kidney Dis. 72, 
682–690 (2018).
13. Dhaun, N., Goddard, J. & Webb, D. J. The endothelin 
system and its antagonism in chronic kidney disease. 
J. Am. Soc. Nephrol. 17, 943–955 (2006).
14. Gerstein, H. C. et al. Albuminuria and risk of 
cardiovascular events, death, and heart failure in 
diabetic and nondiabetic individuals. JAMA 286, 
421–426 (2001).
15. Perkovic, V. et al. Canagliflozin and renal outcomes  
in type 2 diabetes and nephropathy. N. Engl. J. Med. 
380, 2295–2306 (2019).
16. Heerspink, H. J. L. et al. Dapagliflozin in patients  
with chronic kidney disease. N. Engl. J. Med. 383, 
1436–1446 (2020).
17. Jafar, T. H. et al. Progression of chronic kidney 
disease: the role of blood pressure control, 
proteinuria, and angiotensin- converting enzyme 
inhibition. A patient- level meta- analysis. Ann. Intern. 
Med. 139, 244–252 (2003).
18. O’Dowd, B. F. et al. A human gene that shows identity 
with the gene encoding the angiotensin receptor is 
located on chromosome 11. Gene 136, 355–360 
(1993).
19. Sun, X. et al. Non- activated APJ suppresses the 
angiotensin II type 1 receptor, whereas apelin- 
activated APJ acts conversely. Hypertens. Res. 34, 
701–706 (2011).
20. Yang, R. et al. Apelin/APJ axis improves angiotensin  
II- induced endothelial cell senescence through  
AMPK/SIRT1 signaling pathway. Arch. Med. Sci. 14, 
725–734 (2018).
21. Ishida, J. et al. Regulatory roles for APJ, a seven- 
transmembrane receptor related to angiotensin- type 
1 receptor in blood pressure in vivo. J. Biol. Chem. 
279, 26274–26279 (2004).
22. Iwanaga, Y., Kihara, Y., Takenaka, H. & Kita, T. Down- 
regulation of cardiac apelin system in hypertrophied 
and failing hearts: possible role of angiotensin  
II–angiotensin type 1 receptor system. J. Mol.  
Cell Cardiol. 41, 798–806 (2006).
23. Siddiquee, K. et al. Apelin protects against 
angiotensin II- induced cardiovascular fibrosis and 
decreases plasminogen activator inhibitor type-1 
production. J. Hypertens. 29, 724–731 (2011).
24. Barnes, G. D. et al. Sustained cardiovascular actions 
of APJ agonism during renin–angiotensin system 
activation and in patients with heart failure.  
Circ. Heart Fail. 6, 482–491 (2013).
25. Sato, T. et al. ELABELA–APJ axis protects from 
pressure overload heart failure and angiotensin  
II- induced cardiac damage. Cardiovasc. Res. 113, 
760–769 (2017).
26. Zhang, Z. Z. et al. Apelin is a negative regulator  
of angiotensin II- mediated adverse myocardial 
remodeling and dysfunction. Hypertension 70,  
1165–1175 (2017).
27. Wang, W. et al. Apelin protects against abdominal 
aortic aneurysm and the therapeutic role of neutral 
endopeptidase resistant apelin analogs. Proc. Natl 
Acad. Sci. USA 116, 13006–13015 (2019).
28. Read, C. et al. International Union of Basic and Clinical 
Pharmacology. CVII. Structure and pharmacology of 
the apelin receptor with a recommendation that 
elabela/toddler is a second endogenous peptide 
ligand. Pharmacol. Rev. 71, 467–502 (2019).
29. Tucker, B. et al. Zebrafish angiotensin II receptor- like 
1a (agtrl1a) is expressed in migrating hypoblast, 
vasculature, and in multiple embryonic epithelia.  
Gene Expr. Patterns 7, 258–265 (2007).
30. Scott, I. C. et al. The G protein- coupled receptor 
agtrl1b regulates early development of myocardial 
progenitors. Dev. Cell 12, 403–413 (2007).
31. Kalin, R. E. et al. Paracrine and autocrine mechanisms 
of apelin signaling govern embryonic and tumor 
angiogenesis. Dev. Biol. 305, 599–614 (2007).
32. Tatemoto, K. et al. Isolation and characterization of a 
novel endogenous peptide ligand for the human APJ 
receptor. Biochem. Biophys. Res. Commun. 251, 
471–476 (1998).
33. Lee, D. K. et al. Characterization of apelin, the  
ligand for the APJ receptor. J. Neurochem. 74, 34–41 
(2000).
34. Chng, S. C., Ho, L., Tian, J. & Reversade, B. ELABELA: 
a hormone essential for heart development signals via 
the apelin receptor. Dev. Cell 27, 672–680 (2013).
35. Pauli, A. et al. Toddler: an embryonic signal that 
promotes cell movement via Apelin receptors. Science 
343, 1248636 (2014).
36. Maguire, J. J., Kleinz, M. J., Pitkin, S. L. &  
Davenport, A. P. [Pyr1]apelin-13 identified as the 
predominant apelin isoform in the human heart: 
vasoactive mechanisms and inotropic action in 
disease. Hypertension 54, 598–604 (2009).
37. Zhen, E. Y., Higgs, R. E. & Gutierrez, J. A. 
Pyroglutamyl apelin-13 identified as the major apelin 
isoform in human plasma. Anal. Biochem. 442, 1–9 
(2013).
38. Shin, K., Pandey, A., Liu, X. Q., Anini, Y. & Rainey, J. K. 
Preferential apelin-13 production by the proprotein 
convertase PCSK3 is implicated in obesity. FEBS 
Open. Bio 3, 328–333 (2013).
39. Fischer, C. et al. Plasma kallikrein cleaves and 
inactivates apelin-17: palmitoyl- and PEG- extended 
apelin-17 analogs as metabolically stable blood 
pressure- lowering agents. Eur. J. Med. Chem. 166, 
119–124 (2019).
40. Murza, A., Belleville, K., Longpre, J. M., Sarret, P.  
& Marsault, E. Stability and degradation patterns of 
chemically modified analogs of apelin-13 in plasma 
and cerebrospinal fluid. Biopolymers 102, 297–303 
(2014).
41. McKinnie, S. M. et al. The metalloprotease neprilysin 
degrades and inactivates apelin peptides. 
Chembiochem 17, 1495–1498 (2016).
42. Velazquez, E. J. et al. Angiotensin–neprilysin inhibition 
in acute decompensated heart failure. N. Engl. J. Med. 
380, 539–548 (2019).
43. Vickers, C. et al. Hydrolysis of biological peptides by 
human angiotensin- converting enzyme- related 
carboxypeptidase. J. Biol. Chem. 277, 14838–14843 
(2002).
44. Wang, W. et al. Angiotensin- converting enzyme 2 
metabolizes and partially inactivates Pyr- Apelin-13 
and Apelin-17: physiological effects in the 
cardiovascular system. Hypertension 68, 365–377 
(2016).
45. Yang, P. et al. [Pyr(1)]Apelin-13(1–12) is a 
biologically active ACE2 metabolite of the endogenous 
cardiovascular peptide [Pyr(1)]Apelin-13. Front. 
Neurosci. 11, 92 (2017).
Nature reviews | Nephrology
R e v i e w s
0123456789();: 
46. Hamming, I. et al. Tissue distribution of ACE2 protein, 
the functional receptor for SARS coronavirus. A first 
step in understanding SARS pathogenesis. J. Pathol. 
203, 631–637 (2004).
47. Donoghue, M. et al. A novel angiotensin- converting 
enzyme- related carboxypeptidase (ACE2) converts 
angiotensin I to angiotensin 1–9. Circ. Res. 87, E1–E9 
(2000).
48. Li, W. et al. Angiotensin- converting enzyme 2 is a 
functional receptor for the SARS coronavirus. Nature 
426, 450–454 (2003).
49. To, K. F. & Lo, A. W. Exploring the pathogenesis of 
severe acute respiratory syndrome (SARS): the tissue 
distribution of the coronavirus (SARS- CoV) and its 
putative receptor, angiotensin- converting enzyme 2 
(ACE2). J. Pathol. 203, 740–743 (2004).
50. Benton, D. J. et al. Receptor binding and priming of 
the spike protein of SARS- CoV-2 for membrane fusion. 
Nature 588, 327–330 (2020).
51. Nyimanu, D. et al. Development and validation of an 
LC–MS/MS method for detection and quantification  
of in vivo derived metabolites of [Pyr(1)]apelin-13  
in humans. Sci. Rep. 9, 19934 (2019).
52. Charo, D. N. et al. Endogenous regulation of 
cardiovascular function by apelin- APJ. Am. J. Physiol. 
Heart Circ. Physiol 297, H1904–H1913 (2009).
53. Zeng, X. X., Wilm, T. P., Sepich, D. S. & Solnica- Krezel, L. 
Apelin and its receptor control heart field formation 
during zebrafish gastrulation. Dev. Cell 12, 391–402 
(2007).
54. Freyer, L. et al. Loss of apela peptide in mice causes 
low penetrance embryonic lethality and defects  
in early mesodermal derivatives. Cell Rep. 20,  
2116–2130 (2017).
55. Sharma, B. et al. Alternative progenitor cells 
compensate to rebuild the coronary vasculature  
in Elabela- and APJ- deficient hearts. Dev. Cell 42, 
655–666 e653 (2017).
56. Yang, P. et al. Elabela/toddler is an endogenous 
agonist of the apelin APJ receptor in the adult 
cardiovascular system, and exogenous administration 
of the peptide compensates for the downregulation of 
its expression in pulmonary arterial hypertension. 
Circulation 135, 1160–1173 (2017).
57. Hosoya, M. et al. Molecular and functional 
characteristics of APJ. Tissue distribution of mRNA 
and interaction with the endogenous ligand apelin.  
J. Biol. Chem. 275, 21061–21067 (2000).
58. O’Carroll, A. M., Selby, T. L., Palkovits, M. & Lolait, S. J. 
Distribution of mRNA encoding B78/apj, the rat 
homologue of the human APJ receptor, and its 
endogenous ligand apelin in brain and peripheral 
tissues. Biochim. Biophys. Acta 1492, 72–80 (2000).
59. Medhurst, A. D. et al. Pharmacological and 
immunohistochemical characterization of the  
APJ receptor and its endogenous ligand apelin.  
J. Neurochem. 84, 1162–1172 (2003).
60. Dray, C. et al. Apelin and APJ regulation in adipose 
tissue and skeletal muscle of type 2 diabetic mice and 
humans. Am. J. Physiol. Endocrinol. Metab. 298, 
E1161–1169 (2010).
61. Katugampola, S. D., Maguire, J. J., Matthewson, S. R.  
& Davenport, A. P. [(125)I]-(Pyr(1))Apelin-13 is a novel 
radioligand for localizing the APJ orphan receptor in 
human and rat tissues with evidence for a vasoconstrictor 
role in man. Br. J. Pharmacol. 132, 1255–1260 (2001).
62. Kleinz, M. J., Skepper, J. N. & Davenport, A. P. 
Immunocytochemical localisation of the apelin 
receptor, APJ, to human cardiomyocytes, vascular 
smooth muscle and endothelial cells. Regul. Pept. 
126, 233–240 (2005).
63. Wang, G. et al. Apelin, a new enteric peptide: 
localization in the gastrointestinal tract, ontogeny,  
and stimulation of gastric cell proliferation and  
of cholecystokinin secretion. Endocrinology 145, 
1342–1348 (2004).
64. Kleinz, M. J. & Davenport, A. P. Immunocytochemical 
localization of the endogenous vasoactive peptide 
apelin to human vascular and endocardial endothelial 
cells. Regul. Pept. 118, 119–125 (2004).
65. Marsault, E. et al. The apelinergic system: a 
perspective on challenges and opportunities in 
cardiovascular and metabolic disorders. Ann. N. Y. 
Acad. Sci. 1455, 12–33 (2019).
66. Boucher, J. et al. Apelin, a newly identified adipokine 
up- regulated by insulin and obesity. Endocrinology 
146, 1764–1771 (2005).
67. Kawamata, Y. et al. Molecular properties of apelin: 
tissue distribution and receptor binding. Biochim. 
Biophys. Acta 1538, 162–171 (2001).
68. Deng, C., Chen, H., Yang, N., Feng, Y. & Hsueh, A. J. 
Apela regulates fluid homeostasis by binding to the 
APJ receptor to activate Gi signaling. J. Biol. Chem. 
290, 18261–18268 (2015).
69. O’Carroll, A. M. et al. Expression and functional 
implications of the renal apelinergic system in rodents. 
PLoS ONE 12, e0183094 (2017).
70. Perjes, A. et al. Characterization of apela, a novel 
endogenous ligand of apelin receptor, in the adult 
heart. Basic. Res. Cardiol. 111, 2 (2016).
71. Wang, Z. et al. Elabela–apelin receptor signaling 
pathway is functional in mammalian systems. Sci. Rep. 
5, 8170 (2015).
72. El Messari, S. et al. Functional dissociation of apelin 
receptor signaling and endocytosis: implications  
for the effects of apelin on arterial blood pressure.  
J. Neurochem. 90, 1290–1301 (2004).
73. Nyimanu, D. et al. Apelin-36-[L28A] and Apelin-
36-[L28C(30kDa- PEG)] peptides that improve diet 
induced obesity are G protein biased ligands at the 
apelin receptor. Peptides 121, 170139 (2019).
74. McKinnie, S. M. K. et al. Synthetic modification within 
the “RPRL” region of apelin peptides: impact on 
cardiovascular activity and stability to neprilysin and 
plasma degradation. J. Med. Chem. 60, 6408–6427 
(2017).
75. Read, C. et al. Apelin peptides linked to anti- serum 
albumin domain antibodies retain affinity in vitro and 
are efficacious receptor agonists in vivo. Basic. Clin. 
Pharmacol. Toxicol. 126 (Suppl 6), 96–103 (2020).
76. Langelaan, D. N., Bebbington, E. M., Reddy, T. & 
Rainey, J. K. Structural insight into G- protein  
coupled receptor binding by apelin. Biochemistry 48, 
537–548 (2009).
77. Macaluso, N. J., Pitkin, S. L., Maguire, J. J., 
Davenport, A. P. & Glen, R. C. Discovery of a 
competitive apelin receptor (APJ) antagonist. 
ChemMedChem 6, 1017–1023 (2011).
78. Murza, A. et al. Elucidation of the structure–activity 
relationships of apelin: influence of unnatural amino 
acids on binding, signaling, and plasma stability. 
ChemMedChem 7, 318–325 (2012).
79. Zhang, Y. et al. Identifying structural determinants  
of potency for analogs of apelin-13: integration of  
C- terminal truncation with structure–activity. Bioorg 
Med. Chem. 22, 2992–2997 (2014).
80. Ma, Y. et al. Structural basis for apelin control of the 
human apelin receptor. Structure 25, 858–866.e854 
(2017).
81. Langelaan, D. N. et al. Structural features of the apelin 
receptor N- terminal tail and first transmembrane 
segment implicated in ligand binding and receptor 
trafficking. Biochim. Biophys. Acta 1828, 1471–1483 
(2013).
82. Gerbier, R. et al. New structural insights into  
the apelin receptor: identification of key residues  
for apelin binding. FASEB J. 29, 314–322 (2015).
83. Couvineau, P., Llorens- Cortes, C. & Iturrioz, X.  
Elabela/Toddler and apelin bind differently to the 
apelin receptor. Faseb j. 34, 7989–8000 (2020).
84. Habata, Y. et al. Apelin, the natural ligand of the 
orphan receptor APJ, is abundantly secreted in  
the colostrum. Biochim. Biophys. Acta 1452, 25–35 
(1999).
85. Masri, B., Lahlou, H., Mazarguil, H., Knibiehler, B.  
& Audigier, Y. Apelin (65–77) activates extracellular 
signal- regulated kinases via a PTX- sensitive G protein. 
Biochem. Biophys. Res. Commun. 290, 539–545 
(2002).
86. Masri, B., Morin, N., Pedebernade, L., Knibiehler, B.  
& Audigier, Y. The apelin receptor is coupled to Gi1  
or Gi2 protein and is differentially desensitized by  
apelin fragments. J. Biol. Chem. 281, 18317–18326 
(2006).
87. Hashimoto, Y. et al. G protein- coupled APJ receptor 
signaling induces focal adhesion formation and cell 
motility. Int. J. Mol. Med. 16, 787–792 (2005).
88. Szokodi, I. et al. Apelin, the novel endogenous ligand 
of the orphan receptor APJ, regulates cardiac 
contractility. Circ. Res. 91, 434–440 (2002).
89. Dray, C. et al. Apelin stimulates glucose utilization in 
normal and obese insulin- resistant mice. Cell Metab. 
8, 437–445 (2008).
90. Evans, N. A. et al. Visualizing differences in ligand- 
induced beta- arrestin-GFP interactions and trafficking 
between three recently characterized G protein- 
coupled receptors. J. Neurochem. 77, 476–485 
(2001).
91. Lee, D. K., Ferguson, S. S., George, S. R. &  
O’Dowd, B. F. The fate of the internalized apelin 
receptor is determined by different isoforms of apelin 
mediating differential interaction with beta- arrestin. 
Biochem. Biophys. Res. Commun. 395, 185–189 
(2010).
92. Zhou, N. et al. Cell–cell fusion and internalization of 
the CNS- based, HIV-1 co- receptor, APJ. Virology 307, 
22–36 (2003).
93. Wootten, D., Christopoulos, A., Marti- Solano, M., 
Babu, M. M. & Sexton, P. M. Mechanisms of signalling 
and biased agonism in G protein- coupled receptors. 
Nat. Rev. Mol. Cell Biol. 19, 638–653 (2018).
94. Scimia, M. C. et al. APJ acts as a dual receptor in 
cardiac hypertrophy. Nature 488, 394–398 (2012).
95. Japp, A. G. et al. Vascular effects of apelin in vivo in 
man. J. Am. Coll. Cardiol. 52, 908–913 (2008).
96. Japp, A. G. et al. Acute cardiovascular effects of apelin 
in humans: potential role in patients with chronic 
heart failure. Circulation 121, 1818–1827 (2010).
97. Brame, A. L. et al. Design, characterization, and  
first- in-human study of the vascular actions of a novel 
biased apelin receptor agonist. Hypertension 65, 
834–840 (2015).
98. Pope, G. R., Tilve, S., McArdle, C. A., Lolait, S. J.  
& O’Carroll, A. M. Agonist- induced internalization  
and desensitization of the apelin receptor. Mol. Cell 
Endocrinol. 437, 108–119 (2016).
99. Murza, A. et al. Discovery and structure–activity 
relationship of a bioactive fragment of ELABELA that 
modulates vascular and cardiac functions. J. Med. Chem. 
59, 2962–2972 (2016).
100. Wang, W. et al. Loss of Apelin exacerbates myocardial 
infarction adverse remodeling and ischemia–
reperfusion injury: therapeutic potential of synthetic 
Apelin analogues. J. Am. Heart Assoc. 2, e000249 
(2013).
101. Read, C. et al. Cardiac action of the first G protein 
biased small molecule apelin agonist. Biochem. 
Pharmacol. 116, 63–72 (2016).
102. Ason, B. et al. Cardiovascular response to small 
molecule APJ activation. JCI Insight 5, e132898 
(2020).
103. Salcedo, A. et al. Apelin effects in human splanchnic 
arteries. Role of nitric oxide and prostanoids. Regul. 
Pept. 144, 50–55 (2007).
104. Lee, D. K. et al. Modification of the terminal residue  
of apelin-13 antagonizes its hypotensive action. 
Endocrinology 146, 231–236 (2005).
105. Tatemoto, K. et al. The novel peptide apelin lowers 
blood pressure via a nitric oxide- dependent 
mechanism. Regul. Pept. 99, 87–92 (2001).
106. Wang, C., Du, J. F., Wu, F. & Wang, H. C. Apelin 
decreases the SR Ca2+ content but enhances the 
amplitude of [Ca2+]i transient and contractions during 
twitches in isolated rat cardiac myocytes. Am. J. 
Physiol. Heart Circ. Physiol 294, H2540–H2546 
(2008).
107. Perjes, A. et al. Apelin increases cardiac contractility 
via protein kinase Cepsilon- and extracellular signal- 
regulated kinase- dependent mechanisms. PLoS ONE 
9, e93473 (2014).
108. Kuba, K. et al. Impaired heart contractility in Apelin 
gene- deficient mice associated with aging and 
pressure overload. Circ. Res. 101, e32–42 (2007).
109. Farkasfalvi, K. et al. Direct effects of apelin on 
cardiomyocyte contractility and electrophysiology. 
Biochem. Biophys. Res. Commun. 357, 889–895 
(2007).
110. Ashley, E. A. et al. The endogenous peptide apelin 
potently improves cardiac contractility and reduces 
cardiac loading in vivo. Cardiovasc. Res. 65, 73–82 
(2005).
111. Sato, T. et al. Apelin is a positive regulator of ACE2 in 
failing hearts. J. Clin. Invest. 123, 5203–5211 (2013).
112. Sato, T. et al. Loss of apelin augments angiotensin  
II- induced cardiac dysfunction and pathological 
remodeling. Int J Mol Sci 20, 239 (2019).
113. Cheng, C. C. et al. Apelin regulates the 
electrophysiological characteristics of atrial myocytes. 
Eur. J. Clin. Invest. 43, 34–40 (2013).
114. Cox, C. M., D’Agostino, S. L., Miller, M. K.,  
Heimark, R. L. & Krieg, P. A. Apelin, the ligand for  
the endothelial G- protein-coupled receptor, APJ, is a 
potent angiogenic factor required for normal vascular 
development of the frog embryo. Dev. Biol. 296,  
177–189 (2006).
115. Kidoya, H. et al. Spatial and temporal role of the 
apelin/APJ system in the caliber size regulation of 
blood vessels during angiogenesis. EMBO J. 27,  
522–534 (2008).
116. Kasai, A. et al. Retardation of retinal vascular 
development in apelin- deficient mice. Arterioscler. 
Thromb. Vasc. Biol. 28, 1717–1722 (2008).
117. Eyries, M. et al. Hypoxia- induced apelin expression 
regulates endothelial cell proliferation and 
regenerative angiogenesis. Circ. Res. 103, 432–440 
(2008).
www.nature.com/nrneph
R e v i e w s
0123456789();: 
118. Ronkainen, V. P. et al. Hypoxia inducible factor 
regulates the cardiac expression and secretion  
of apelin. FASEB J. 21, 1821–1830 (2007).
119. Adam, F. et al. Apelin: an antithrombotic factor  
that inhibits platelet function. Blood 127, 908–920 
(2016).
120. Zhang, G. et al. Biphasic roles for soluble guanylyl 
cyclase (sGC) in platelet activation. Blood 118,  
3670–3679 (2011).
121. Masoud, A. G. et al. Apelin directs endothelial cell 
differentiation and vascular repair following immune- 
mediated injury. J. Clin. Invest. 130, 94–107 (2020).
122. Cheng, H. et al. Involvement of apelin/APJ axis in 
thrombogenesis in valve heart disease patients with 
atrial fibrillation. Int. Heart J. 60, 145–150 (2019).
123. Chun, H. J. et al. Apelin signaling antagonizes Ang II 
effects in mouse models of atherosclerosis. J. Clin. 
Invest. 118, 3343–3354 (2008).
124. Hashimoto, T. et al. Requirement of apelin–apelin 
receptor system for oxidative stress- linked 
atherosclerosis. Am. J. Pathol. 171, 1705–1712 
(2007).
125. Japp, A. G. & Newby, D. E. The apelin–APJ system  
in heart failure: pathophysiologic relevance and 
therapeutic potential. Biochem. Pharmacol. 75, 
1882–1892 (2008).
126. Földes, G. et al. Circulating and cardiac levels of 
apelin, the novel ligand of the orphan receptor APJ,  
in patients with heart failure. Biochem. Biophys. Res. 
Commun. 308, 480–485 (2003).
127. Chong, K. S., Gardner, R. S., Morton, J. J., Ashley, E. A. 
& McDonagh, T. A. Plasma concentrations of the  
novel peptide apelin are decreased in patients with 
chronic heart failure. Eur. J. Heart Fail. 8, 355–360 
(2006).
128. Chen, M. M. et al. Novel role for the potent 
endogenous inotrope apelin in human cardiac 
dysfunction. Circulation 108, 1432–1439 (2003).
129. Fukushima, H., Kobayashi, N., Takeshima, H.,  
Koguchi, W. & Ishimitsu, T. Effects of olmesartan on 
apelin/APJ and Akt/endothelial nitric oxide synthase 
pathway in dahl rats with end- stage heart failure.  
J. Cardiovasc. Pharmacol. 55, 83–88 (2010).
130. Berry, M. F. et al. Apelin has in vivo inotropic  
effects on normal and failing hearts. Circulation 110, 
II187–II193 (2004).
131. Azizi, Y., Faghihi, M., Imani, A., Roghani, M. &  
Nazari, A. Post- infarct treatment with [Pyr1]-apelin-13 
reduces myocardial damage through reduction of 
oxidative injury and nitric oxide enhancement in the 
rat model of myocardial infarction. Peptides 46, 
76–82 (2013).
132. Kido, M. et al. Hypoxia- inducible factor 1-alpha 
reduces infarction and attenuates progression of 
cardiac dysfunction after myocardial infarction in the 
mouse. J. Am. Coll. Cardiol. 46, 2116–2124 (2005).
133. Abbasloo, E., Najafipour, H. & Vakili, A. Chronic 
treatment with apelin, losartan and their combination 
reduces myocardial infarct size and improves cardiac 
mechanical function. Clin. Exp. Pharmacol. Physiol. 
47, 393–402 (2020).
134. Ellinor, P. T., Low, A. F. & Macrae, C. A. Reduced  
apelin levels in lone atrial fibrillation. Eur. Heart J. 27, 
222–226 (2006).
135. Gurger, M. et al. The association between apelin-12 
levels and paroxysmal supraventricular tachycardia.  
J. Cardiovasc. Med. 15, 642–646 (2014).
136. Falcone, C. et al. Apelin plasma levels predict 
arrhythmia recurrence in patients with persistent 
atrial fibrillation. Int. J. Immunopathol. Pharmacol. 
23, 917–925 (2010).
137. Kim, Y. M. et al. Apelin increases atrial conduction 
velocity, refractoriness, and prevents inducibility of 
atrial fibrillation. JCI Insight 5, e126525 (2020).
138. Watanabe, H. et al. Close bidirectional relationship 
between chronic kidney disease and atrial fibrillation: 
the Niigata preventive medicine study. Am. Heart J. 
158, 629–636 (2009).
139. Ananthapanyasut, W. et al. Prevalence of atrial 
fibrillation and its predictors in nondialysis patients 
with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 
5, 173–181 (2010).
140. Kumar, S. et al. Anticoagulation in concomitant 
chronic kidney disease and atrial fibrillation: JACC 
review topic of the week. J. Am. Coll. Cardiol. 74, 
2204–2215 (2019).
141. Hus- Citharel, A. et al. Effect of apelin on glomerular 
hemodynamic function in the rat kidney. Kidney Int. 
74, 486–494 (2008).
142. Reaux- Le Goazigo, A., Morinville, A., Burlet, A., 
Llorens- Cortes, C. & Beaudet, A. Dehydration- induced 
cross- regulation of apelin and vasopressin 
immunoreactivity levels in magnocellular  
hypothalamic neurons. Endocrinology 145,  
4392–4400 (2004).
143. Reaux, A. et al. Physiological role of a novel 
neuropeptide, apelin, and its receptor in the rat brain. 
J. Neurochem. 77, 1085–1096 (2001).
144. De Mota, N. et al. Apelin, a potent diuretic 
neuropeptide counteracting vasopressin actions 
through inhibition of vasopressin neuron activity and 
vasopressin release. Proc. Natl Acad. Sci. USA 101, 
10464–10469 (2004).
145. Azizi, M. et al. Reciprocal regulation of plasma apelin 
and vasopressin by osmotic stimuli. J. Am. Soc. 
Nephrol. 19, 1015–1024 (2008).
146. Hus- Citharel, A. et al. Apelin counteracts vasopressin- 
induced water reabsorption via cross talk between 
apelin and vasopressin receptor signaling pathways  
in the rat collecting duct. Endocrinology 155,  
4483–4493 (2014).
147. Boulkeroua, C. et al. Apelin-13 regulates vasopressin- 
induced aquaporin-2 expression and trafficking in 
kidney collecting duct cells. Cell Physiol. Biochem. 53, 
687–700 (2019).
148. Sawhney, S. et al. Intermediate and long- term 
outcomes of survivors of acute kidney injury episodes: 
a large population- based cohort study. Am. J. Kidney 
Dis. 69, 18–28 (2017).
149. Hoste, E. A. et al. Epidemiology of acute kidney injury 
in critically ill patients: the multinational AKI- EPI 
study. Intensive Care Med. 41, 1411–1423 (2015).
150. See, E. J. et al. Long- term risk of adverse outcomes 
after acute kidney injury: a systematic review and 
meta- analysis of cohort studies using consensus 
definitions of exposure. Kidney Int. 95, 160–172 
(2019).
151. Chen, H. et al. Apelin protects against acute renal 
injury by inhibiting TGF- beta1. Biochim. Biophys. Acta 
1852, 1278–1287 (2015).
152. Gholampour, F., Bagheri, A., Barati, A., Masoudi, R.  
& Owji, S. M. Remote ischemic perconditioning 
modulates apelin expression after renal ischemia–
reperfusion injury. J. Surg. Res. 247, 429–437 
(2020).
153. Sagiroglu, T. et al. Effects of apelin and leptin on renal 
functions following renal ischemia/reperfusion: an 
experimental study. Exp. Ther. Med. 3, 908–914 
(2012).
154. Kim, J. S. et al. Protective role of apelin against 
cyclosporine- induced renal tubular injury in rats. 
Transpl. Proc. 49, 1499–1509 (2017).
155. Chen, H. et al. ELABELA and an ELABELA fragment 
protect against AKI. J. Am. Soc. Nephrol. 28,  
2694–2707 (2017).
156. Couser, W. G., Remuzzi, G., Mendis, S. & Tonelli, M. 
The contribution of chronic kidney disease to the 
global burden of major noncommunicable diseases. 
Kidney Int. 80, 1258–1270 (2011).
157. Muller, T. et al. Apelinergic system in the kidney: 
implications for diabetic kidney disease. Physiol. Rep. 
6, e13939 (2018).
158. Guo, C. et al. Apelin promotes diabetic nephropathy 
by inducing podocyte dysfunction via inhibiting 
proteasome activities. J. Cell Mol. Med. 19,  
2273–2285 (2015).
159. Day, R. T., Cavaglieri, R. C. & Feliers, D. Apelin retards 
the progression of diabetic nephropathy. Am. J. 
Physiol. Ren. Physiol 304, F788–F800 (2013).
160. Zhang, B. H., Wang, W., Wang, H., Yin, J. & Zeng, X. J. 
Promoting effects of the adipokine, apelin, on diabetic 
nephropathy. PLoS ONE 8, e60457 (2013).
161. Hu, H., He, L., Li, L. & Chen, L. Apelin/APJ system as  
a therapeutic target in diabetes and its complications. 
Mol. Genet. Metab. 119, 20–27 (2016).
162. Chen, H. et al. Apelin inhibits the development of 
diabetic nephropathy by regulating histone acetylation 
in Akita mouse. J. Physiol. 592, 505–521 (2014).
163. Zhang, J., Yin, J., Wang, Y., Li, B. & Zeng, X. Apelin 
impairs myogenic response to induce diabetic 
nephropathy in mice. FASEB J. 32, 4315–4327 
(2018).
164. Liu, Y., Zhang, J., Wang, Y. & Zeng, X. Apelin involved 
in progression of diabetic nephropathy by inhibiting 
autophagy in podocytes. Cell Death Dis. 8, e3006 
(2017).
165. Blanchard, A. et al. An abnormal apelin/vasopressin 
balance may contribute to water retention in patients 
with the syndrome of inappropriate antidiuretic 
hormone (SIADH) and heart failure. J. Clin. Endocrinol. 
Metab. 98, 2084–2089 (2013).
166. Urwyler, S. A. et al. Plasma apelin concentrations in 
patients with polyuria–polydipsia syndrome. J. Clin. 
Endocrinol. Metab. 101, 1917–1923 (2016).
167. Lacquaniti, A. et al. Apelin and copeptin: two  
opposite biomarkers associated with kidney function 
decline and cyst growth in autosomal dominant 
polycystic kidney disease. Peptides 49, 1–8  
(2013).
168. Kocer, D., Karakukcu, C., Ozturk, F., Eroglu, E. & 
Kocyigit, I. Evaluation of fibrosis markers: apelin  
and transforming growth factor- beta1 in autosomal 
dominant polycystic kidney disease patients.  
Ther. Apher. Dial. 20, 517–522 (2016).
169. Nogueira, A., Pires, M. J. & Oliveira, P. A. 
Pathophysiological mechanisms of renal fibrosis:  
a review of animal models and therapeutic strategies. 
Vivo 31, 1–22 (2017).
170. Wang, Y. et al. beta- Arrestin-biased AT1R stimulation 
promotes extracellular matrix synthesis in renal 
fibrosis. Am. J. Physiol. Ren. Physiol 313, F1–F8 
(2017).
171. Maschio, G. et al. Effect of the angiotensin- converting-
enzyme benazepril on the progression of chronic  
renal insufficiency. N. Engl. J. Med. 334, 939–945 
(1996).
172. Xu, C. et al. ELABELA antagonizes intrarenal renin–
angiotensin system to lower blood pressure and 
protects against renal injury. Am. J. Physiol. Ren. 
Physiol 318, F1122–F1135 (2020).
173. Wang, L. Y. et al. The regulatory peptide apelin: a novel 
inhibitor of renal interstitial fibrosis. Amino Acids 46, 
2693–2704 (2014).
174. Schreiber, C. A., Holditch, S. J., Generous, A. &  
Ikeda, Y. Sustained ELABELA gene therapy in high- salt 
diet- induced hypertensive rats. Curr. Gene Ther. 16, 
349–360 (2017).
175. Nishida, M. et al. The role of apelin on the alleviative 
effect of angiotensin receptor blocker in unilateral 
ureteral obstruction- induced renal fibrosis. Nephron 
Extra 2, 39–47 (2012).
176. Castan- Laurell, I., Masri, B. & Valet, P. The apelin/APJ 
system as a therapeutic target in metabolic  
diseases. Expert. Opin. Ther. Targets 23, 215–225 
(2019).
177. Bertrand, C., Valet, P. & Castan- Laurell, I. Apelin and 
energy metabolism. Front. Physiol. 6, 115 (2015).
178. US National Library of Medicine. ClinicalTrials.gov 
https://clinicaltrials.gov/ct2/show/NCT03956576 
(2018).
179. Sorli, S. C., Le Gonidec, S., Knibiehler, B. &  
Audigier, Y. Apelin is a potent activator of tumour 
neoangiogenesis. Oncogene 26, 7692–7699  
(2007).
180. Picault, F. X. et al. Tumour co- expression of apelin and 
its receptor is the basis of an autocrine loop involved 
in the growth of colon adenocarcinomas. Eur. J. Cancer 
50, 663–674 (2014).
181. Heo, K. et al. Hypoxia- induced up- regulation of apelin 
is associated with a poor prognosis in oral squamous 
cell carcinoma patients. Oral. Oncol. 48, 500–506 
(2012).
182. Berta, J. et al. Apelin expression in human non- small 
cell lung cancer. Role in angiogenesis and prognosis.  
J. Thorac. Oncol., 1120–1129 (2010).
183. Uribesalgo, I. et al. Apelin inhibition prevents resistance 
and metastasis associated with anti- angiogenic therapy. 
EMBO Mol. Med. 11, e9266 (2019).
184. Davenport, A. P. et al. First in human study of a novel 
biased apelin receptor ligand, MM54, A G- alpha(i) 
agonist/beta- arrestin antagonist. Circ. Res. 123, 
e69–e81 (2018).
185. Harford- Wright, E. et al. Pharmacological targeting  
of apelin impairs glioblastoma growth. Brain 140, 
2939–2954 (2017).
186. Mastrella, G. et al. Targeting APLN/APLNR improves 
antiangiogenic efficiency and blunts proinvasive side 
effects of VEGFA/VEGFR2 blockade in glioblastoma. 
Cancer Res. 79, 2298–2313 (2019).
187. Soulet, F. et al. ELA/APELA precursor cleaved by furin 
displays tumor suppressor function in renal cell 
carcinoma through mTORC1 activation. JCI Insight 5, 
2298 (2020).
188. Patel, S. J. et al. Identification of essential genes for 
cancer immunotherapy. Nature 548, 537–542 (2017).
189. Tolkach, Y. et al. Apelin and apelin receptor expression 
in renal cell carcinoma. Br. J. Cancer 120, 633–639 
(2019).
190. Yau, J. W. Y. et al. Global prevalence and major risk 
factors of diabetic retinopathy. Diabetes Care 35, 
556–564 (2012).
191. Lu, Q., Feng, J. & Jiang, Y. R. The role of apelin  
in the retina of diabetic rats. PLoS ONE 8, e69703 
(2013).
192. Qin, D., Zheng, X.-X. & Jiang, Y.-R. Apelin-13 induces 
proliferation, migration, and collagen I mRNA in 
Nature reviews | Nephrology
R e v i e w s
0123456789();: 
human RPE cells via PI3K/Akt and MEK/Erk  
signalling pathways. Mol. Vis. 2013, 2227–2236 
(2013).
193. Tao, Y. et al. Apelin in plasma and vitreous and in 
fibrovascular retinal membranes of patients with 
proliferative diabetic retinopathy. Invest. Ophthalmol. 
Vis. Sci. 51, 4237–4242 (2010).
194. Du, J. H. et al. Elevation of serum apelin-13 
associated with proliferative diabetic retinopathy  
in type 2 diabetic patients. Int. J. Ophthalmol. 7, 
968–973 (2014).
195. Kasai, A. et al. Inhibition of apelin expression switches 
endothelial cells from proliferative to mature state in 
pathological retinal angiogenesis. Angiogenesis 16, 
723–734 (2013).
Acknowledgements
F.A.C. is supported by a Kidney Research UK Training 
Fellowship (TF_006_20171124). D.N., J.J.M. and A.P.D. are 
supported in whole or part by the Wellcome Trust (WT203814/
Z/16/A for D.N.; WT107715/Z/15/Z for A.P.D. and J.J.M.). 
D.E.N. is supported by the British Heart Foundation 
(FS/06/064, FS/09/019, CH09/002, RG/16/10/32375, 
RE/18/5/34216) and Wellcome Trust (WT103782AIA). N.D. is 
supported by a Senior Clinical Research Fellowship from the 
Chief Scientist Office (SCAF/19/02).
Author contributions
All authors contributed to researching the data, discussing 
the content, writing the text and reviewing or editing the 
manuscript before submission.
Competing interests
The authors declare no competing interests.
Peer review information
Nature Reviews Nephrology thanks Mirjam Christ- Crain, who 
co- reviewed with Sophie Monnerat, and the other, anony-
mous, reviewer(s) for their contribution to the peer review of 
this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional 
claims in published maps and institutional affiliations.
 
© Springer Nature Limited 2021
www.nature.com/nrneph
R e v i e w s
